Key result
Macaranga barteri leaf extract demonstrates potent in vitro antiviral activity against echovirus 7 and 19.
Why the study?
There is no specific drug treatment or vaccine available for echovirus infections, and screening medicinal plants may identify potent antiviral compounds.
Effect estimate: IC50 0.028 ng/mL (E7) and 0.0017 ng/mL (E19)
Macaranga barteri extracts demonstrate potent in vitro antiviral activity against echoviruses E7 and E19, suggesting potential as a therapeutic agent for enteroviral infections.
Macaranga barteri extracts showed potent in vitro activity vs E7/E19; leaves open clinical translation pending in vivo and safety studies.
Echoviruses, a serotype of enteroviruses, infect millions of people globally and there is no specific drug treatment or vaccine available for its management. The screening of medicinal plants used locally for the treatment of infectious diseases, can provide a reliable option in the discovery of potent therapeutic compounds. This study was carried out to investigate the antiviral activities of 27 medicinal plant extracts, belonging to 26 different plant species, selected from Nigerian ethnobotany, against echovirus 7, 13 and 19 serotypes (E7, E13 and E19, respectively). The plants were macerated in methanol and the cytotoxicities of the crude extracts were evaluated on the rhabdomyosarcoma cell line using the MTT assay. The antiviral activity of the plant extracts and fractions against echoviruses (E7, E13, and E19) was determined using the neutralisation assay, an assay that measures the inhibition of cytopathic effect on cell culture. The crude extract of Macaranga barteri leaves had the highest cytotoxicity with CC 50 value of 0.27 μg/mL. This was followed by Crinum jagus (9.88 μg/mL) and Terminalia ivorensis (12.14 μg/mL). The antiviral screening showed that ten out of the 27 crude plant extracts tested were active on E7 and E19, inhibiting the cytopathic effect of the virus in tissue culture. None of the extracts inhibited the cytopathic effect caused by E13 serotype. Amongst the active plant extracts, the methanol extract of M. barteri leaves had the highest antiviral activity on both E7 and E9 with IC 50 values of 0.028 and 0.0017 ng/mL, respectively, followed by the Ageratum conyzoides extract (0.208 μg/mL, E7; 0.006 μg/mL, E19) and Mondia whitei extract (0.038 μg/mL, E7; 0.005 μg/mL, E19). Amongst the fractions of M. barteri, the DCM fraction was most the active and selective on E7 (IC 50 = 0.0075 ng/mL; SI = 19,896.54) and E19 (IC 50 = 0.0175 ng/mL; SI = 8581.24). Our research has demonstrated that Macaranga barteri extracts has potent antiviral activity against echoviruses E7 and E19, and our findings suggest that this extract may have potential as a therapeutic agent in the treatment of enteroviral infections.
No takes yet. Share an insight, caveat, or question.
Ogbole et al. (2018) studied Echovirus infection (in vitro). Macaranga barteri extract vs. Virus control (no extract) was evaluated on 50% inhibition concentration (IC50) (IC50 0.028 ng/mL (E7) and 0.0017 ng/mL (E19)). The methanol extract of Macaranga barteri leaves demonstrated potent in vitro antiviral activity against echovirus 7 and 19 with IC50 values of 0.028 ng/mL and 0.0017 ng/mL, respectively.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: